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EXPRESSION OF IGPR-1 IN ENDOTHELIAL CELLS REGULATES CELL 
SURVIVAL 
JORDAN SHAFRAN 
ABSTRACT 
Angiogenesis is a physiological process by which new blood vessels develop from 
preexisting vasculature.  The process of converting endothelial cells into fully 
developed blood vessels involves multiple coordinated cellular events that occur 
through the collaboration that exists between a variety of growth factors, receptors 
and adhesion molecules.  The immunoglobulin-containing and proline rich 
receptor-1 (IGPR-1) is an IgSF containing adhesion molecule that has been 
recently identified as a novel regulator of angiogenesis in vitro.  In this study, we 
provide evidence that IGPR-1 promotes cell survival in porcine aortic endothelial 
cells (PAE) and plays a role in the inhibition of p38 MAPK in vitro.  Deletion of the 
extracellular domain of IGPR-1 abolished IGPR-1’s ability to inhibit 
phosphorylation of p38 MAPK and promote the survival of endothelial cells.  
Likewise, mutation of serines 186 (A186-IGPR-1) and 220 (A220-IGPR-1) on the 
cytoplasmic domain of IGPR-1 was also found to reduce both the promotion of 
cell survival and inhibition of p38 MAPK.  These findings suggest that both 
domains of IGPR-1 are important for endothelial cell survival and the activation 
p38 MAPK.  
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INTRODUCTION 
 
 Angiogenesis is a biological process by which newly developed capillaries 
form from preexisting vessels (Bischoff, 1996).  The progression from preexisting 
vessels to newly developed capillaries is a complex process that requires the 
stimulation and survival of endothelial cells (ECs) by growth factors and 
receptors, the degradation and invasion of the extracellular matrix, the migration 
and proliferation of ECs and finally the formation of new capillary tubes (Chavakis 
and Dimmeler, 2002).  Under normal physiological conditions angiogenesis is 
important for embryonic development, wound healing and the menstrual cycle, 
however, pathologically, angiogenesis plays an important role in age-related 
macular degeneration, rheumatoid arthritis and tumor metastasis (Isner and 
Losordo, 1999).  At the intersection of this paradigm are mechanisms that 
promote angiogenesis, a dynamic process that centers on the relationship that 
exists between ECs and a variety of growth factors and cell adhesion molecules 
(Meyer et al., 2006; Carmeliet and Jain, 2011).    
 As discussed above, the effects that growth factors and their 
corresponding receptors have on ECs are paramount in the angiogenic process.  
Pro-angiogenic growth factors that have been shown to play important roles for 
creating new vessels include vascular endothelial growth factors (VEGFs), 
fibroblast growth factors (FGFs), platelet derived growth factors (PDGFs), 
angiopoitens (Angs) and matrix metalloproteinases (MMPs) (Gory-Faure et al., 
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1999; Rahimi, 2006; Chavakis and Dimmeler, 2002).  While each of these and 
many other growth factors play a specific role in the development of capillaries 
and blood vessels, VEGFs and FGFs are two of the more prominent stimulators 
of the angiogenic process.  
The VEGF family is comprised of seven different isoforms VEGF-A, 
VEFG-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F, PIGF and three tyrosine kinase 
receptors VEGFR-1, VEGFR-2, VEGFR-3 (Hoeben et al., 2004).  While each 
VEGF isoform is unique in terms of both the amount expressed and the tissue 
expressed in, each are highly potent mitogens for stimulating angiogenesis 
(Hoeben et al., 2004).  In vitro studies have demonstrated that ECs in the 
presence of VEGF are capable of differentiating into structures resembling 
capillaries (Prior et al., 2004).  This biological process is made possible through 
the binding of a VEGF ligand to the cell surface receptor, VEGFR-2, which to 
date, is the most important receptor for VEGF-induced mitogenesis (Hoeben et 
al., 2004).  Activation of VEGFR-2 occurs through receptor dimerization, which 
induces a strong tyrosine kinase signaling cascade that produces an increase in 
EC proliferation, differentiation and permeability (Ferrara, 2001).  Furthermore, 
studies using serum-starved ECs and ligands specific to VEGFR-2 have also 
shown that VEGF is capable of promoting EC survival by means of activating the 
PI3-kinase/Akt signal transduction pathway (Gerber et al., 1998).   
Another important pro-angiogenic factor that is similar in function to VEGF 
is FGF.  At present, the FGF family is comprised of at least 20 isoforms, with the 
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most prominent being FGF-1 and FGF-2 or basic fibroblast growth factor (bFGF) 
(Cross and Claesson-Welsh, 2001).  Unlike VEGF, which strictly binds to one of 
three receptors, FGF isoforms bind to one of four tyrosine kinase FGF receptors 
(FGFR-1, FGFR-2, FGFR-3 and FGFR-4) (Cross and Claesson-Welsh, 2001).  
The binding of FGF’s to an FGFR occurs at the receptors at the cell surface and 
is assisted by heparin sulfate proteoglycans (HSPGs) (Cross and Claesson-
Welsh, 2001).  HSPGs act as co-receptors for FGFs and are located both at the 
cell surface and within the extracellular matrix (ECM) (Cross and Claesson-
Welsh, 2001).  Similar to VEGFR, upon receptor-ligand interaction, the FGFR 
dimerizes and autophosphorylates where it then activates a variety of signal 
transduction pathways, which include PLCy, Ras, and p38 MAPK (Matsumoto et 
al., 2002; Goldfarb, 2001).  Activation of these pathways induces EC 
proliferation, differentiation, migration and survival (Matsumoto et al., 2002; 
Goldfarb, 2001;Cross and Claesson-Welsh, 2001).  Furthermore, both FGF-1 
and FGF-2 also assist in initiating wound healing and do so by stimulating the 
proliferation and differentiation of endothelial and fibroblast cells (Werner and 
Grose, 2003). 
Whereas growth factors are traditionally thought of as the main drivers for 
creating new vessels, studies have also shown that cell adhesion molecules 
(CAMs) play an equally important role in the angiogenic process.  Consisting 
primarily of four distinct families - cadherins, selectins, integrins and 
immunoglobulin superfamily (IgSF) - cell adhesion molecules or adhesion 
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receptors are cell surface glycoproteins that function by regulating cell-cell and 
cell-extracellular matrix adhesion (Juliano, 2002).  While each member of the 
CAM family is unique in terms of their structure and function, the ability of these 
proteins to assist in different aspects of the angiogenic process is made possible 
through the domains that make up their transmembrane structure (Alberts et al., 
2002). 
Integrins are large heterodimeric glycoproteins made up of α and β 
subunits and are expressed on the surface of EC (Luscinskas and Lawler, 1994).  
Their expression on the surface of ECs helps facilitate cell migration and the 
formation of capillary tubes in vitro (Luscinskas and Lawler, 1994).  αvβ3, a 
specific integrin complex, has been shown to be active in growing vessels and 
acts as an adhesive receptor for the ECM components fibronectin, vitronectin 
and thrombospondin (Bischoff, 1996).  By linking ECs to the surrounding ECM, 
integrins not only assist in cellular movement, but they also help maintain the 
survival of newly forming vessels (Weis and Cheresh, 2011).  Multiple studies 
using anti-αv mAbs have effectively inhibited angiogenesis in vitro, thus 
confirming the importance integrins have in facilitating the growth of new vessels 
(Brooks et al., 1994; Friendlander et al., 1995).  While the extracellular domain of 
integrins is responsible for regulating ligand binding specificity, the cytoplasmic 
domain helps facilitate signaling pathways that control EC adhesion, migration 
and survival (Weis and Cheresh, 2011).  Furthermore, studies have also shown 
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that growth factor signaling pathways from both VEFG and bFGF are able to 
enhance the expression of multiple integrins (Somanath et al., 2009).   
In addition to integrins, members of the cadherin family have also been 
linked to angiogenesis (Dejana, 1996).  Vascular endothelial cadherin (VE-
Cadherin) is an endothelium specific calcium dependent cell-cell adhesion 
transmembrane glycoprotein (Bach et al., 1998).  During capillary tube formation, 
VE-cadherins help provide structural integrity to growing vessels by localizing at 
intercellular junctions (Bach et al., 1998).  By localizing at points of contact 
between ECs, newly matured vessels are not only able to maintain their 
structural integrity but also retain their necessary permeability (Dejana et al., 
2008).  Also, similar to the aforementioned relationship that exists between 
VEGF and certain integrins, VE-cadherin and VEFG have a signaling relationship 
of their own.  As mentioned above, VEGF signaling helps promote EC survival 
through the PI3K/Akt pathway (Gerber et al., 1998).  Of significance to this 
signaling pathway is evidence that suggests that VE-cadherin mediates this 
survival pathway through β-catenin (Carmeliet et al., 1999).  In vitro studies have 
shown that inactivation of the VE-cadherin gene reduces the survival benefits 
VEGF provides to ECs (Carmeliet et al., 1999).  This further illustrates the types 
of crosstalk that exists between growth factors and CAMs and the level of 
complexity that is required in order to create new blood vessels.  
The immunoglobulin (Ig) superfamily of proteins is another group of 
adhesion molecules that are known for playing important roles in endothelial cell-
	  6 
cell adhesion and migration during the angiogenic process (Rahimi et al., 2012).  
As the name suggests, Ig- containing adhesion molecules posses an 
extracellular immunoglobulin domain, as well as a single transmembrane domain 
and cytoplasmic domain (Aplin et al., 1998).  IgSF family members are 
expressed on a variety of tissues, including the endothelium, and mediate their 
adhesive properties by binding to the extracellular domains of other Ig-like 
molecules (homophilic adhesion) or to integrins and carbohydrates (heterophilic 
adhesion) (Barclay, 2003).  Examples of IgSF molecules that play functional 
roles in the angiogenic process include, intercellular adhesion molecule-1 (ICAM-
1), vascular cell adhesion molecule-1 (VCAM-1) and platelet endothelial cell 
adhesion molecule-1 (PECAM-1) (Enciso et al., 2003; Rajesh et al., 2005).  Both 
ICAM-1 and VCAM-1 have been shown to facilitate EC migration by mediating 
the adhesion of leukocytes to the endothelia (Deng et al., 2007; Ding et al., 
2003).  This is a critically important function early on in angiogenesis because it 
provides ECs polarity (Kevil et al., 2004).  Similarly, PECAM-1 has also been 
shown to regulate EC migration though interactions that exist between the 
tyrosine phosphatase SHP-2 and the immunoreceptor tyrosine-based inhibitor 
motif (ITIM) located on the molecules cytoplasmic domain (Gratzinger et al., 
2003).  Interactions at this site result in the dephosphorylation of specific 
tyrosines, and as a result the coordinated migration of ECs is made possible 
(Gratzinger et al., 2003).  
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 In this study, I examined a novel IgSF molecule termed immunoglobulin-
containing and proline-rich receptor-1 (IGPR-1) and explored the role it has in 
both cell survival and angiogenesis.  Previous studies have shown that IGPR-1 is 
a 252 amino acid cell surface receptor, and contains a single extracellular Ig 
domain, a single transmembrane domain and a 110 amino acid proline rich 
cytoplasmic domain.  IGPR-1 is expressed in multiple tissue types including 
epithelial and endothelial tissues.  In ECs, IGPR-1 was found to regulate cell-cell 
interactions, inhibit cell migration and promote capillary tube formation in vitro by 
associating with several SH3-containing proteins (Rahimi et al., 2012).  
Throughout this study I present data that shows that IGPR-1 plays a role in 
promoting EC survival, while also inhibiting the activation of p38 MAPK.  The 
significance of these findings further validates the role IGPR-1 has in promoting 
angiogenesis and also provides a potentially new avenue for inhibiting a pro-
angiogenic pathway in select cancers.  
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Figure 1: IGPR-1 promotes endothelial cell survival 	  	   	   	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	   	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  
	  	  	  	  	  	  
FIGURE 1: IGPR-1 promotes endothelial cell survival.  (A) Expression of 
IGPR-1 in PAE cells and protein loading control.  (B)  Ectopic expression of 
IGPR-1 in PAE cells promotes cell survival.  Cell viability was measured by 
MTT assay.  Error bars indicate range. 
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Figure 2: Extracellular domain of IGPR-1 is required for endothelial cell survival 
 
 	  	  
	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  
 
 	  	  
FIGURE 2: Extracellular domain of IGPR-1 is required for endothelial cell 
survival.  (A) Expression of IGPR-1 and ΔN-IGPR-1 in PAE cells and protein 
loading control.  (B)  Ectopic expression of N-terminus-deleted IGPR-1 
eliminates IGPR-1’s ability to promote cell survival.  Cell viability was 
measured by MTT assay.  Error bars indicate range. 
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Figure 3: Serine 186 and 220 on IGPR-1 is required for endothelial cell survival 	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
 	  	  	  	  	  	  
 
 
FIGURE 3: Serine 186 and 220 on IGPR-1 is required for endothelial 
cell survival.  (A) Expression of IGPR-1, A186 IGPR-1 and A220 IGPR-1 
in PAE cells and protein loading control.  (B)  Site-directed mutagenesis to 
serines 186 and 220 on IGPR-1 reduces IGPR-1’s ability to promote cell 
survival.  Cell viability was measured by MTT assay.  Error bars indicate 
range. 
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Figure 4: IGPR-1 inhibits the activation of p38 MAPK in endothelial cells 
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FIGURE 4: IGPR-1 inhibits the activation of p38 MAPK in endothelial 
cells.  (A,B,C) Cell lysates derived from PAE cells expressing empty 
vector and IGPR-1 were immunoblotted with anti-phospho-p38 MAPK 
(A), anti-p38 MAPK (B), and PLCγ1 for protein loading control. 
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Figure 5: Extracellular domain of IGPR-1 is required for inhibiting p38 MAPK 
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FIGURE 5: Extracellular domain of IGPR-1 is required for the 
inhibition p38 MAPK.  (A,B,C) Cell lysates derived from PAE cells 
expressing empty vector, IGPR-1 and ΔN-IGPR-1 were immunoblotted 
with anti-phospho-p38 MAPK (A), anti-p38 MAPK (B), and PLCγ1 for 
protein loading control. 
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Figure 6: Serine 186 and 220 on IGPR-1 is required for the inhibition of p38 MAPK 
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FIGURE 6: Serine 186 and 220 on IGPR-1 is required for the inhibition of 
p38 MAPK.  (A,B,C) Cell lysates derived from PAE cells expressing empty 
vector, IGPR-1, A186-IGPR-1 and A220-IGPR-1 were immunoblotted with anti-
phospho-p38 MAPK (A), anti-p38 MAPK (B), and PLCγ1 for protein loading 
control. 
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METHODS 
 
Reagents and Antibodies 
Rabbit polyclonal anti-IGPR-1 antibody was developed as previously described 
(Rahimi et al., 2012).  Rabbit polyclonal IgG anti-phospho-p38 MAPK 
(Thr180/Tyr 182) antibody was purchased from Cell Signaling Technology 
(Beverly, MA).  The following antibodies were purchased from Santa Cruz 
Biotechnology Inc. (Santa Cruz, CA): polyclonal IgG anti-p38α/β MAPK, rabbit 
polyclonal IgG anti-PLCγ1, rabbit polyclonal IgG anti-IQGAP1 and pre-adsorbed 
goat anti-rabbit IgG- horseradish peroxidase.  The MTT cell viability assay kit, 
CellTiter 96 Non-Radioactive Cell Proliferation Assay, was purchased from 
Promega (Madison, WI). 
Plasmids 
Porcine aortic cells (PAE) expressing empty vector (pMSCV), IGPR-1 or N-
terminus-truncated IGPR-1 (ΔN-IGPR-1) were generated using a 
pMSCV.puromyocin vector as previously described (Rahimi et al., 2012). 
Cell Culture 
PAE cells were grown in Dulbecco’s modified essential medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS), and penicillin and 
streptomycin.  All cells were incubated at 37°C, 5% CO2 in a humidified chamber.   
Site-Directed Mutagenesis  
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PAE cell lines expressing mutations at serine sites 186 and 220 were generated 
previously using a PCR-based site-directed mutagenesis strategy (R. Meyer, 
unpublished). 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay  
Endothelial cell survival was measured using a 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay kit (Promega) as described previously 
(Hartsough et al., 2010).  Briefly, PAE cells (4-5 x 104 ) expressing empty vector 
(pMSCV), IGPR-1, ΔN-IGPR-1, A186-IGPR-1 and A220-IGPR-1 were seeded 
into 24-well tissue culture plates and serum starved for 0-8 days.  Cells were 
then incubated with an MTT yellow tetrazole dye at a concentration of 5µL/100uL 
of media for 2 hours at 37°C.  Insoluble purple formazan that was produced 
during incubation was then solubilized with the addition of “Stop Solution”.  
Solubilized solution from the wells was then transferred to a 96-well plate for 
spectrophotometric analysis at 570 nm.  Conditions for plates were carried out in 
quadruplet.   
Western Blot Analysis 
PAE cells were grown to confluent conditions in 10% DMEM, lysed and then 
subjected to Western blot analysis as described previously (Meyer et al., 2011).  
Briefly, PAE cells expressing empty vector (pMSCV), IGPR-1, ΔN-IGPR-1, A186-
IGPR-1 and A220-IGPR-1 were put on ice and washed three times with ice-cold 
H/S buffer (25 mM HEPES, pH 7.4, 150 mM NaCl, 2 mM Na3VO4).  Cells were 
then lysed and collected in 1.5 mL Eppendorff tubes using lysis (EB) buffer (10 
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mM Tris-HCl, pH 7.4, 5 mM EDTA, 50 mM NaCl, 50 mM NaF, 1% Triton X-100, 1 
mM phenylmethylsulfonyl fluoride, 2 mM Na3VO4, and 20 µg/ml aprotinin).  
Whole-cell lysates were then heated at 95°C for 5 minutes in Laemmli sample 
buffer, resolved by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), 
transferred onto polyvinylidene difluoride (PVDF) membranes, and 
immunoblotted for proteins of interest using IGPR-1 antibody or the antibodies 
indicated in the figure legends.  
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RESULTS 
 
 
IGPR-1 promotes endothelial cell survival 
IGPR-1 is expressed in endothelial and epithelial cells and its expression in ECs 
is known to regulate angiogenesis.  IGPR-1 also is known to regulate cell-cell 
adhesion (Rahimi et al., 2012), a process that is important for cell survival 
(Mutstonen & Alitalo, 1995; Chavakis and Dimmeler, 2002).  The potential role of 
IGPR-1 in EC survival is not known.  To test the hypothesis that IGPR-1 
regulates EC survival, I examined whether ectopic expression of IGPR-1 in 
porcine aortic endothelial (PAE) cells could promote cell survival.   
To demonstrate the ectopic expression of IGPR-1 in PAE cells, whole cell 
lysates derived from PAE cells that had been previously transduced to express 
IGPR-1 (IGPR-1/PAE) or an empty vector (pMSCV/PAE) were first harvested 
and subjected to Western blot analysis using an anti-IGPR-1 antibody (Figure 
1A).  As shown in Fig. 1A, cell lysates derived from PAE cells overexpressing 
IGPR-1 were positive for IGPR-1, whereas PAE cells expressing an empty vector 
showed no expression of IGPR-1.  This data confirms that PAE cells transduced 
to express IGPR-1 are successfully expressing ectopic IGPR-1.  PlCγ1 was used 
as a loading control.   
To determine whether ectopic expression of IGPR-1 in ECs promotes 
survival, pMSCV/PAE and IGPR-1/PAE cells were subjected to an MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide) cell viability assay (Figure 
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1B).  Quantitative analysis based on the number of viable cells showed that PAE 
cells overexpressing IGPR-1 had a 65% increase in cell survival when compared 
to PAE cells expressing empty vector (Figure 1B).  This data suggests that the 
ectopic expression of IGPR-1 in PAE cells promotes EC survival. 
Extracellular domain of IGPR-1 is required for endothelial cell survival 
IGPR-1 is a transmembrane cell adhesion receptor consisting of a single 
extracellular Ig domain (Rahimi et al., 2012).  Upon deletion of the Ig domain, 
ECs expressing Ig domain deleted IGPR-1 (ΔN-IGPR-1) are no longer capable of 
forming cell-cell interactions (Rahimi et al., 2012.).  Data has shown that the Ig 
domain facilitates protein-protein and cell-cell interactions (Barclay, 2003; Rahimi 
2006), and that cell-cell interactions are important for the regulation of EC 
survival (Limaye et al., 2005).  Given that is has been shown that deletion of the 
Ig domain negates IGPR-1’s ability to mediate cell-cell interaction in PAE cells, 
and knowing that cell-cell interaction is a mediator of EC survival, I hypothesized 
that the extracellular domain on IGPR-1 was needed for the promotion of survival 
in ECs. 
To investigate whether the extracellular domain of IGPR-1 was needed to 
promote EC survival, whole cell lysates derived from PAE cells overexpressing 
IGPR-1, empty vector and IGPR-1 with the extracellular domain deleted (ΔN-
IGPR-1) were subjected to Western blot analysis using an anti-IGPR-1 antibody 
(Figure 2A).  PAE cells overexpressing IGPR-1 expressed IGPR-1 at the 
expected molecular weight of 56 kDa, whereas PAE cells expressing ΔN-IGPR-1 
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expressed IGPR-1 at a weight of 23 kDa (Figure 2A).  IQGAP-1 was used as a 
loading control.   
To determine whether the deletion of the extracellular domain on IGPR-1 
reduces survival in PAE cells, PAE cells expressing an empty vector, IGPR-1 
and ΔN-IGPR-1 were subjected to an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5 
diphenyl tetrazolium bromide) cell viability assay (Figure 3B).  Similar to the 
results found in Figure 1B, PAE cells expressing ectopic IGPR-1 had a 40% 
greater survival rate when compared to PAE cells expressing an empty vector 
(Figure 2B).  Interestingly, PAE cells expressing ΔN-IGPR-1 had a 25% reduction 
in survival when compared to PAE cells expressing ectopic IGPR-1, yet when 
compared to PAE cells expressing an empty vector it only had a 13% increase in 
survival (Figure 2B).  Taken together, this data suggests that in order for IGPR-1 
to fully promote the survival of ECs, IGPR-1 must contain the Ig extracellular 
domain. 
Serine 186 and 220 on IGPR-1 are required for endothelial cell survival 
IGPR-1 contains a 110-amino acid cytoplasmic domain (Rahimi et al., 2012). 
Positioned along the cytoplasmic domain at the amino sites 186 and 220 are 
serine residues (N. Rahimi, unpublished data).  Both S186 and S220 have shown 
the capability of being phosphorylated (N. Rahimi, unpublished data).  Research 
has shown that phosphorylated serines located within proline rich sequences of 
receptors are necessary for the tight associations that exist between a receptor 
and a partnering signaling protein (Williamson, 1994).  Further, data has also 
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indicated that most phosphoproteins in eukaryotic cells contain more then one 
phosphorylatable site, and that multisite phosphorylation is an important regulator 
of protein function (Salazar and Hofer, 2009).  To test the hypothesis that both 
serine 186 and 220 are equally important for the survival of ECs, I examined 
whether inducing site-directed mutagenesis on serines 186 and 220 on IGPR-1 
in PAE cells would affect PAE cells ability to promote EC survival. 
To examine this concept, whole cell lysates derived from PAE cells 
expressing an empty vector, ectopic IGPR-1 or IGPR-1 with serines 186 and 220 
mutated into alanines (A186-IGPR1 and A220-IGPR-1) were harvested and 
subjected to Western blot analysis using an anti-IGPR-1 antibody (Figure 3A).  
As shown in Fig 3A, PAE cells expressing A186-IGPR-1 and A220-IGPR-1 
expressed IGPR-1 at 56 kDa, the expected molecular weight of IGPR-1.  IQGAP-
1 was used as a loading control.    
To determine whether mutating serine residues 186 and 220 of the 
cytoplasmic domain on IGPR-1 into alanine residues affected survival in PAE 
cells, PAE cells expressing an empty vector, IGPR-1, A186-IGPR-1 and A220-
IGPR-1 were subjected to an MTT cell viability assay (Figure 3B).  PAE cells 
expressing ectopic IGPR-1 had a 36% increase in cell survival when compared 
to PAE cells expressing A186-IGPR-1 and an 84% increase in cell survival when 
compared to PAE cells expressing A220-IGPR-1 (Figure 3B).  Further, PAE cells 
expressing A220-IGPR-1 exhibited almost identical survival rates when 
compared to PAE cells expressing an empty vector (Figure 3B).  This data 
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indicates that mutating serine residue 220 to alanine on IGPR-1 significantly 
reduces IGPR-1’s ability to promote EC survival, whereas mutating serine 
residue 186 only partially reduces IGPR-1’s ability to promote cell survival.  
Taken together, this data suggests that serine residue 220 plays a more 
prominent role in promoting EC survival.   
IGPR-1 inhibits the activation of p38 MAPK in endothelial cells 
Expression of IGPR-1 in PAE cells inhibits cell migration, a process that has 
been shown to correlate with the dephosphorylation of paxillin (Rahimi et al., 
2012).  Data has shown that paxillin functions as an adapter protein for multiple 
cell migration signaling pathways, including JNK, Erk and p38 (Huang et al., 
2004), and that the phosphorylation of paxillin increases cell migration (Abou 
Zeid et al., 2006).  Of particular interest, p38 MAPK, a signaling protein that is 
known to mediate migration, cell survival and angiogenesis (Huang et al., 2004; 
Gutiérrez-Uzquiza et al., 2012; Matsumoto et al., 2002), has been shown to 
directly interact with and phosphorylate paxillin (Huang et al., 2004).  Due to the 
correlation that exists between IGPR-1 and paxillin, and the connection between 
p38 MAPK and paxillin, I hypothesized that IGPR-1 facilitates the inactivation of 
p38 MAPK.   
To examine whether IGPR-1 inhibits the activation of p38 MAPK, whole 
cell lysates derived from PAE cells expressing an empty vector or ectopic IGPR-
1 were subjected to Western blot analysis using anti-phospho-p38 MAPK 
antibody (Figure 4).  As shown in Fig. 4, expression of ectopic IGPR-1 in PAE 
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cells produced a reduction in the amount of phosphorylated p38 MAPK, whereas 
PAE cells expressing an empty vector expressed a higher amount of 
phosphorylated p38 MAPK.  Taken together, this data suggests that the ectopic 
expression of IGPR-1 in PAE cells inhibits the activation of p38 MAPK.  PAE 
cells expressing ectopic IGPR-1 and an empty vector were also subjected to 
Western blot analysis using anti-p38 MAPK antibody.  Data from this western blot 
shows equal expression of p38 MAPK from both cell populations.  Plcy1 was 
used as a loading control.   
Extracellular domain of IGPR-1 is required for the inhibition of p38 MAPK 
As discussed above, IGPR-1 contains a single Ig extracellular domain (Rahimi et 
al., 2012).  In addition to regulating cellular morphology, focal adhesion (Rahimi 
et al., 2012) and cell survival (Figure 2B), the extracellular domain of IGPR-1 has 
also been shown to mediate homophilic cell-cell interaction (Rahimi et al., 2012).  
The significance of homophilic cell-cell interaction, particularly in the case of PAE 
cells expressing IGPR-1, is that it enables IGPR-1 to become activated through 
trans-dimerization (N. Rahimi, unpublished data) while also allowing cells to 
aggregate and adhere tightly to one another (Rahimi et al., 2012).  As a result, 
IGPR-1 is able to induce a variety of cellular responses, including the inhibition of 
cellular migration and the promotion of capillary tube formation and angiogenesis 
(Rahimi et al., 2012).  Given that the proposed model for IGPR-1’s own activation 
involves trans-dimerization, while also recognizing the relationship that exists 
between p38 MAPK activation and IGPR-1, I hypothesized that the Ig 
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extracellular domain of IGPR-1 is required in order to inhibit the activation of p38 
MAPK. 
To investigate whether the extracellular domain of IGPR-1 was needed to 
inhibit the activation of p38 MAPK, whole cell lysates derived from PAE cells 
overexpressing IGPR-1, empty vector and IGPR-1 with the extracellular domain 
deleted were subjected to Western blot analysis using anti-phospho-p38 MAPK 
antibody (Figure 5).  Whole cell lysates from PAE cells expressing wild-type 
IGPR-1 were able to inhibit the phosphorylation of p38 MAPK, whereas PAE 
cells expressing an empty vector failed inhibit p38 MAPK phosphorylation (Figure 
5).  Interestingly, ΔN-IGPR-1 lysates produced equal amounts of phospho-p38 
MAPK when compared to PAE cells expressing an empty vector.  This suggests 
that the extracellular domain of IGPR-1 is needed in order for IGPR-1 to inhibit 
the activation of p38 MAPK.  PAE cells expressing IGPR-1, pMSCV and ΔN-
IGPR-1 were also subjected to Western blot analysis using anti-p38 MAPK 
antibody.  Data from this western blot shows equal expression of p38 MAPK from 
all cell populations.  Plcy1 was used as a loading control.   
Serine 186 and 220 on IGPR-1 is required for the inhibition of p38 MAPK 
The cytoplasmic domain of IGPR-1 contains a proline-rich motif (Rahimi et al., 
2012).  Dispersed throughout this motif are multiple serine sites, including 
serines 186 and 220, both of which were shown to being important for promoting 
EC survival (Figure 3B).  In addition to playing a role in promoting cell survival, 
the proline rich region of IGPR-1 has also been shown to interact with SPIN90, 
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an SH3 containing signaling protein (Rahimi et al., 2012).  SPIN90 is known for 
playing a key role in cell adhesion, actin cytoskeleton reorganization (Lim et al., 
2001; Takenawa and Suetsugu, 2007), and angiogenesis (Rahimi et al., 2012).  
SPIN90 is also known for mediating the activation of the small signaling 
GTPases, Rho and Rac (Teodorof et al., 2009).  Further, data has shown that 
Rho and Rac are capable of mediating the activation of p38 MAPK (Zhang et al., 
1995).  Because IGPR-1 interacts with SPIN90 through its SH3 domain at sites 
along the proline-rich motif, and knowing that mutation of serines 186 and 220 
disrupted IGPR-1’s ability to promote survival, I hypothesized that both serines 
186 and 220 were necessary for inhibiting the signaling cascade that potentially 
activates p38 MAPK.  
To examine this possibility whole cell lysates derived from PAE cells 
expressing an empty vector, ectopic IGPR-1 or IGPR-1 with serines 186 and 220 
mutated into alanines were harvested and subjected to Western blot analysis 
using an anti-phospho-p38 MAPK antibody.  As shown in Fig 6, PAE cells that 
expressed either an empty vector, A186-IGPR-1 or A220-IGPR-1 all produced 
equal amounts of phosphorylated p38 MAPK.  Alternatively,  PAE cells 
expressing wild-type IGPR-1 produced a significantly lower amount of activated 
p38 MAPK.  Taken together, this data suggests that both serines 186 and 220 
are equally important for inhibiting the activation of p38 MAPK.  PAE cells 
expressing an empty vector, IGPR-1, A186-IGPR-1 and A220-IGPR-1 were also 
subjected to Western blot analysis using anti-p38 MAPK antibody.  Data from this 
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western blot shows equal expression of p38 MAPK for all cell populations.  
PLCγ1 was used as a loading control. 
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DISCUSSION 
 
In this study I report that IGPR-1, a novel cell surface adhesion receptor, 
promotes cell survival in ECs.  Previous data has shown that IGPR-1 plays an 
integral role in supporting angiogenesis (Rahimi et al., 2012).  Angiogenesis is a 
multistep process through which newly developed capillaries form from 
preexisting vessels (Chavakis and Dimmeler, 2002).  Early in the angiogenic 
process, ECs are stimulated for growth by a variety of growth factors (Isner and 
Losordo, 1999).  Although the process for initiating new blood vessel growth is 
dependent upon growth factor stimulation (Carmeliet, 2000), the maintenance 
and survival of ECs is primarily regulated through interactions that exist between 
adhesion receptors expressed on ECs and the extracellular matrix (Kim et al., 
2002).  This is of particular importance because the promotion of EC survival is 
essential for angiogenesis (Chavakis and Dimmeler, 2002).     
Data presented in this study suggests that IGPR-1 plays a critical role in 
the promotion of survival in ECs.  Transfer of wild-type IGPR-1 into porcine aortic 
endothelial (PAE) cells, produced on average, a 62% greater survival rate when 
compared to PAE cells expressing an empty vector following serum starvation.  
The observed increase in cell survival in PAE cells expressing IGPR-1 can 
largely be attributed to IGPR-1’s adhesive properties.  Previous data has shown 
that expression of IGPR-1 in PAE cells causes an increase in focal adhesion 
(Rahimi et al., 2012).  Increased focal adhesion enables ECs to remain in tight 
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contact with one another, which in addition to many other biological processes, 
helps promote their survival (Rahimi et al., 2012; Dejana et al., 2008).  
Furthermore, the ability of IGPR-1 to promote EC survival strongly correlates with 
other cell adhesion molecules (CAMs), with such examples that include 
CD31/platelet endothelial cell adhesion molecule-1 (PECAM-1), junctional 
adhesion molecule (JAM)-A and intercellular adhesion molecule-2 (ICAM-2) 
(Huang et al., 2005).        
Another important aspect of IGPR-1 in regards to promoting cell survival is 
the role the adhesion molecule has in regulating specific MAPK signaling 
pathways.  As described previously, mitogen-activated protein kinases (MAPK) 
are highly conserved proteins that are involved in the conversion of extracellular 
stimuli - cytokines, growth factors, stress signals - into intracellular responses 
(Roux and Blenis, 2004).  In mammals there are three families of MAP kinases, 
which include ERKs, JNKs and p38 (Morrison, 2012).  Upon activation, MAPKs 
form intracellular signaling cascades through the sequential phosphorylation of a 
MAPK module that consists of a MAPK kinase kinase (MAPKKK), MAPK kinase 
(MAPKK) and MAPK (Wildmann et al., 1999).  Through these highly conserved 
signaling cascades, pathways of all varieties are elicited; including those that 
regulate functions such as motility, gene expression, mitosis, differentiation, 
apoptosis and survival (Roux and Blenis, 2004).   
Of particular interest to this study was the potential relationship 
hypothesized to exist between IGPR-1 and p38 MAPK.  As the name suggests, 
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p38 is a 38-kDa mitogen-activated cytoplasmic protein kinase that undergoes 
rapid tyrosine phosphorylation in response to a variety of stress related stimuli 
(Phong et al., 2010; Han et al., 1994).  Previous research has shown that upon 
activation, p38 translocates from the cytoplasm to the nucleus where it helps 
facilitate normal immune and inflammatory responses (Han et al., 1994).  Of 
more importance to this study is the recent data that suggests that p38 MAPK is 
a major mediator for a signaling pathway that regulates cell migration (Huang et 
al., 2004).  As suggested by Huang et al., 2004, upon stimulation by a variety of 
growth factors, the MAPKK MKK3/6, is activated where it then phosphorylates 
and activates p38 MAPK.  The activation of p38 MAPK enables the kinase to 
phosphorylate paxillin, which then allows paxillin to induce EC migration.  
Consistent with this proposed signaling cascade, coupled with the 
previous findings regarding IGPR-1 and cell migration, data presented in this 
study suggests that IGPR-1 represses the activation of p38 MAPK.  Of interest, 
expression of IGPR-1 in PAE cells produced a significant reduction in the 
phosphorylation of p38 MAPK.  The significance of this data is that matches the 
observed trend with previous findings, in that the expression of IGPR-1 reduced 
the phosphorylation of paxillin. In all likelihood, this is due in part from IGPR-1 
inhibiting p38 MAPK activation (Rahimi et al., 2012).  By providing evidence that 
shows IGPR-1 inhibits the downstream activation of p38 MAPK pathway, the 
proposed signaling cascade outlined previously (IGPR-1-Spin90-Rac/Rho-
MAPKKK-MAPKK-p38) remains as a possible explanation as to how IGPR-1 
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inhibits p38 MAPK.  While more data is needed to determine the validity of this 
proposed signaling cascade, data presented later in this discussion further 
validates this proposed signaling cascade.   
      Continuing to examine the relationship that exists between IGPR-1, 
survival and angiogenesis, this study focused on IGPR-1’s 
extracellular/intracellular domains, and the roles these domains play in both EC 
survival and p38 MAPK inhibition.  Starting with the extracellular domain, data 
has shown that IGPR-1 contains a single Ig domain (Rahimi et al., 2012).  
Mechanistically, Ig domains regulate certain biological activities through the 
formation of homophilic and heterophilic interactions, a feature that is inherent to 
all IgSF adhesion molecules (Barclay, 2003; Rahimi 2006).  In the case of IGPR-
1, the Ig domain was shown to be necessary for inhibiting EC migration and 
forming cell-cell interactions, as evidenced by the molecules in ability to do so 
upon deletion of the domain (Rahimi et al., 2012).  This data, while not all that 
surprising, illustrates the type of regulation Ig domains have.   
Continuing this trend, data presented in this study suggests that the Ig 
domain of IGPR-1 is necessary for both the inhibition of p38 MAPK and 
promotion of EC survival.  When comparing PAE cells expressing wild-type 
IGPR-1 to PAE cells expressing the extracellular deleted form of IGPR-1(ΔN-
IGPR-1), cells with the deleted form of IGPR-1 produced a significantly higher 
amount of activated p38 MAPK.  The explanation for this phenomenon can likely 
be attributed to the process by which IGPR-1 becomes activated.  As discussed 
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above, data has shown that IGPR-1 becomes activated through a process known 
as transdimerization (N. Rahimi, unpublished data), a form of homophilic 
interaction that is regulated by the Ig domain.  If the Ig domain on IGPR-1 is 
required for its own activation, which in turn enables the molecule to interact with 
substrates and signal to downstream effectors, then it logically follows that the 
loss of the Ig domain would disrupt IGPR-1 from inhibiting p38 MAPK activation.  
This is clearly evident as PAE cells expressing ΔN-IGPR-1 produced roughly 
equal amounts of activated p38 MAPK when compared to PAE cells expressing 
an empty vector.  Interestingly, when comparing survival rates between PAE 
cells expressing wild-type IGPR-1 and ΔN-IGPR-1, there was only a 25% 
increase in survival in PAE cells expressing wild-type IGPR-1.  A possible 
explanation for this involves basal activity of IGPR-1, a function that permits 
partial receptor activity without proper activation.  
Moving to the cytoplasmic domain, previous data has shown that IGPR-1 
contains a 110-amino acid proline-rich cytoplasmic domain (Rahimi et al., 2012).  
Positioned along this domain are multiple serine residues, each capable of 
phosphorylation (N.Rahimi, unpublished).  At these proline-rich sites, various 
cytoplasmic SH3 containing signaling proteins have been shown to interact with 
IGPR-1, including Spin90, BPAG1 and CANCB2 (Rahimi et al., 2012).  As a 
result, it has been hypothesized that IGPR-1 inhibits p38 MAPK through its 
interaction with Spin90.  Again to summarize, upon interaction between IGPR-1 
and Spin90, Spin90 recruits the GTPases Rac and Rho, which then disables the 
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signaling complex that activates p38 MAPK.  Central to this proposed signaling 
cascade is the proline-SH3 protein-protein interaction that exists between IGPR-
1 and Spin90.  Research has shown that this form of protein-protein interaction is 
made possible due in part to the proline residues’ ability to both recognize and 
bind to SH3 domains (Yu et al., 1994).  However, it is also known that 
phosphorylated serines within the proline rich sequences are necessary for the 
tight association of these protein complexes (Williamson, 1994).  Therefore, it 
seems likely that certain serine residues residing in the proline rich regions on 
IGPR-1 play an important role in maintaining the inactivation of p38 MAPK. 
In support of this, data presented in this study shows that both serine 
residues 186 and 220 in the proline-rich cytoplasmic domain of IGPR-1 are 
important for maintaining the inactivation of p38 MAPK.  PAE cells expressing 
either A186-IGPR-1 or A220-IGPR-1 failed to inhibit p38 MAPK activation, as 
both cell populations had equal amounts of phosho-p38 MAPK when compared 
to PAE cells expressing an empty vector.  While PAE cells expressing mutations 
to serine residues 186 and 220 on IGPR-1 produced an isoform of IGPR-1 that 
was phenotypically very similar to PAE cells expressing an empty vector in 
regards to p38 activation, this was not the case in their abilities to promote EC 
survival.  While both isoforms of mutated IGPR-1 produced a reduction in EC 
survival when compared to PAE cells expressing wild-type IGPR-1, PAE cells 
expressing A220-IGPR-1 had a much more drastic reduction in survival (84% v 
35%).  While it may seem counterintuitive that certain peptide residues would 
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have larger roles for initiating a biological response, data has shown that that 
most phosphoproteins in eukaryotic cells contain more then one 
phosphorylatable site, and do so for tighter regulation of protein function (Salazar 
and Hofer, 2009).  Taken together, the data suggests that while both serine 
residues 186 and 220 on IGPR-1 are equally important in the regulation p38 
MAPK inhibition, it is serine residue 220 that plays a much more prominent role 
in promoting EC survival. 
In conclusion, data presented throughout this study shows that expression 
of IGPR-1 in PAE cells promotes EC survival in vitro.  Furthermore, IGPR-1 was 
also shown to suppress the phosphorylation and activation of p38 MAPK.  p38 
MAPK has been implicated in a signaling pathway that induces cell migration, 
and data presented throughout this study it illustrates a potential mechanism by 
which IGPR-1 inhibits cell migration.  Inhibiting the activation of p38 MAPK by 
IGPR-1 is dependent upon both the extracellular and intracellular domains of 
IGPR-1, specifically the Ig domain and serine residues 186 and 220.  Loss or 
mutation to either domain affects IGPR-1’s ability to inhibit p38 MAPK activation, 
suggesting that a likely mechanism for inhibition involves a complex consisting of 
IGPR-1, Spin90 and Rac/Rho.  While there is no direct link between EC survival 
and the inhibition of p38 MAPK, logic would suggest that a reduction in cell 
migration would positively correlate with an increase in survival.  By reducing the 
dissociation of ECs from one another in vitro, ECs are able to remain tethered 
together.  This is important for maintaining cell survival as well as other biological 
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processes, including the regulation of capillary tube formation.  While it is evident 
that both domains of IGPR-1 are of equal importance for inhibiting p38 MAPK 
activation, the same cannot be said regarding their effects on EC survival.  
Future studies should continue exploring the role IGPR-1 has in angiogenic 
related diseases, such as cancer, and determine whether inhibition of the 
proposed pathway or other potential pathways could be an effective solution for 
treatment.  
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